Immusoft announces the formation of a scientific advisory board



SEATTLE – (COMMERCIAL THREAD) –Immusoft, a cell therapy company dedicated to improving the lives of rare disease patients, today announced the formation of its Scientific Advisory Board (SAB) made up of world-renowned experts to provide external scientific assessment and high-level advice on the Company’s research and development programs.

The SAB will work closely with the Immusoft management team to advance and expand its leading position in B cells as bio-factories for the delivery of therapeutic proteins, a new approach that Immusoft has pioneered. . The Company is currently preparing for the short-term clinical development of its lead investigational drug candidate ISP-001, a first-class investigational treatment for Hurler syndrome, the most severe form of type 1 mucopolysaccharidosis (MPS I), a rare lysosomal storage disease.

“We are thrilled and privileged to have the opportunity to work with this group of rare disease and cell therapy experts on the development of our pipeline,” said Sean Ainsworth, CEO of Immusoft. “These thought leaders bring a considerable understanding of rare diseases, as well as extensive experience in drug development, from discovery to advanced clinical trials. We look forward to their continued contributions to Immusoft as we enter a new stage in the progression of ISP-001 into clinical trials this year. ”

The members of Immusoft’s Scientific Council are as follows:

Robert Sikorski, MD, Ph.D., is responsible for the SAB and chief consultant of the medical service at Immusoft. Dr Sikorski is currently Managing Director of Woodside Way Ventures, an advisory and investment firm that helps biotech companies and investors advance life-saving technologies through clinical development. Previously, he was Chief Medical Officer of Five Prime Therapeutics (acquired by Amgen). Earlier in his career, he was instrumental in building MedImmune’s oncology portfolio through partnership and acquisition efforts. Prior to joining Medimmune, he led advanced clinical development and post-market efforts for several commercial drugs and drug candidates at Amgen. Dr Sikorski began his career as Associate Researcher Howard Hughes and Visiting Fellow at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate Harold Varmus. In addition, he was editor of the Science and Journal of the American Medical Association. Dr Sikorski received his MD and Ph.D. as a Medical Scientist Education Program Fellow at the Johns Hopkins School of Medicine.

Paula Cannon, Ph.D., is Emeritus Professor of Molecular Microbiology and Immunology at the Keck School of Medicine at the University of Southern California, where she leads a research team studying viruses, stem cells and gene therapy. She received her PhD from the University of Liverpool in the UK and completed postdoctoral training at Oxford and Harvard Universities. His research uses gene editing technologies such as CRISPR / Cas9, to develop treatments for infectious and genetic diseases of the blood and the immune system. In 2010, his team was the first to show that gene editing could be used to mimic a naturally occurring mutation in the CCR5 gene that prevents HIV infection, and which has now been moved to a clinical trial in people living with HIV. .

Michael C. Carroll, Ph.D., is a Principal Investigator at Boston Children’s Hospital and Professor of Pediatrics at Harvard Medical School. His recent research focuses on two major areas, namely neuroimmunology and peripheral autoimmunity. Using mouse models of neuropsychiatric lupus, his group is testing their hypothesis that interferon alpha from peripheral inflammation enters the brain and mediates synaptic loss and symptoms of cognitive decline seen in patients. Following a large genetic screen in patients with schizophrenia, they recently reported that over-activation of a process known as “microglial-mediated complement-dependent synaptic pruning” in new strains of mice can induce malignancies. psychiatric symptoms of schizophrenia. In a model of murine lupus, his lab identified that autoreactive B cells evolve with kinetics similar to that of B cells responding to a foreign antigen, providing a new explanation for the spread of epitopes.. Dr Carroll received his PhD from UT Southwestern Medical School and postgraduate training from Nobel Laureate Professor Rodney R. Porter of the University of Oxford. He is the recipient of awards from the Pew Foundation, the American Arthritis Foundation and the National Alliance for Mental Health.

Hans-Peter Kiem, MD, Ph.D. is the Stephanus Family Chair in Cell and Gene Therapy at the Fred Hutchinson Cancer Research Center. He is a world-renowned pioneer in the field of stem cells and gene therapy and in the development of new gene editing technologies. He focused on developing improved treatments and curative approaches for patients with genetic and infectious diseases or cancer. For gene editing, his lab is working on the design and selection of enzymes, called nucleases, which include CRISPR / Cas. These enzymes work like molecular scissors capable of precisely deactivating defective genes. By combining the ability of gene therapy to repair problem genes and the regenerative abilities of stem cells, he hopes to cure diseases as diverse as HIV, leukemia and brain cancer. He is also a pioneer in in vivo gene therapy approaches to make gene therapy and gene editing more widely available and accessible to patients and people living with HIV, especially in resource-limited settings. He obtained his doctorate in medicine and his doctorate. at the University of Ulm, Germany.

Bruce Levine, Ph.D., Barbara and Edward Netter, Professor of Cancer Gene Therapy, is the founding director of the Clinical Cell and Vaccine Production Facility in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center at the Perelman School of Medicine from the University of Pennsylvania. The first trials of adoptive immunotherapy in humans include the first use of a lentiviral vector, the first infusions of genetically engineered cells, and the first use of engineered lentiviral cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,100 cellular products administered to over 1,300 patients in clinical trials since 1996. Dr. Levine is the recipient of the William Osler Patient Oriented Research Award, Wallace H. Coulter Award for Healthcare Innovation, the National Marrow Donor Program / Be The Match ONE Forum 2020 Dennis Confer Innovate Award, is president of the International Society for Cell and Gene Therapy and a member of the board of directors of the Alliance for Regenerative Medicine . Dr. Levine received a bachelor’s degree in biology from the University of Pennsylvania and a doctorate. in Immunology and Infectious Diseases from Johns Hopkins University.

Peter Sage, Ph.D.., is Assistant Professor of Medicine at Harvard Medical School and Associate Immunologist at Brigham and Women’s Hospital. Dr Sage is also a member of the Committee on Immunology (COI) at Harvard Medical School. Dr Sage received his PhD in Immunology from Harvard Medical School in 2013, during which he received the Jeffrey Modell Prize. He completed a postdoctoral fellowship in the laboratory of Dr Arlene Sharpe of the Department of Immunology at Harvard Medical School in 2017. Dr Sage started his independent laboratory in 2017 at the Transplantation Research Center of the Division of Renal Medicine at Brigham and Hospital women. Dr. Sage’s lab is focused on studying how the immune system controls B-cell and antibody responses in health and disease settings.

About Immusoft

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using prolonged delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP â„¢), which modifies a patient’s B cells and instructs the cells to produce drugs encoded by genes. B cells that are reprogrammed using ISP become miniature drug factories that should survive in patients for many years. The company is based in Seattle, WA. For more information visit www.immusoft.com.


Previous Autonomous labs aren't far, says Microsoft chief researcher at Medlab Middle East
Next EPA announces plans to expand the scope of TRI reporting requirements for ethylene oxide

No Comment

Leave a reply

Your email address will not be published.